Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 2

2(33.3%)

Phase 3

1(16.7%)

6Total

Phase 1(3)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04797780Phase 3Terminated

Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Role: lead

NCT04905407Phase 2Terminated

Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Role: lead

NCT02807558Phase 2Completed

A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Role: lead

NCT04996030Phase 1Suspended

A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

Role: lead

NCT04247126Phase 1Completed

A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

Role: lead

NCT03134638Phase 1Terminated

A Study of SY-1365 in Adult Patients With Advanced Solid Tumors

Role: lead

All 6 trials loaded